All In Biotech

Drug Trial Radar · NCT07223138

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

1,560

Planned (sponsor's estimate)

Start

Nov 13, 2025

Primary completion

Feb 4, 2028

Study completion Feb 4, 2028

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
Oct 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)

Conditions

  • Arthritis, Psoriatic

Interventions

  • SonelokimabDrug

    Open-label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term safety and tolerability of sonelokimab:Time frame: 52 weeks
  2. Long-term safety and tolerability of sonelokimab:Time frame: 52 weeks
  3. Long-term safety and tolerability of sonelokimab:Time frame: 52 weeks
  4. Long-term safety and tolerability of sonelokimab:Time frame: 52 weeks
  5. Long-term safety and tolerability of sonelokimab:Time frame: 52 weeks
  6. Long-term safety and tolerability of sonelokimab:Time frame: 52 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Avondale, Arizona

  • Clinical Site

    Mesa, Arizona

  • Clinical Site

    Phoenix, Arizona

  • Clinical Site

    Scottsdale, Arizona

  • Clinical Site

    Tucson, Arizona

  • Clinical Site

    Jonesboro, Arkansas

  • Clinical Site

    Upland, California

  • Clinical Site

    Avon Park, Florida

  • Clinical Site

    Clearwater, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Baltimore, Maryland

  • Clinical Site

    Charlotte, North Carolina

  • Clinical Site

    Leland, North Carolina

  • Clinical Site

    Middleburg Heights, Ohio

  • Clinical Site

    Duncansville, Pennsylvania

  • Clinical Site

    Memphis, Tennessee

  • Clinical Site

    Baytown, Texas

  • Clinical Site

    Lubbock, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.